The treatment of triple-negative breast cancer remains chemotherapy based and lacks targeted drugs. However, immunotherapy combinations have shown promising activity, targeted chemotherapy options via antibody–drug conjugates are in the clinic, and molecular means of identifying targetable subsets are on the horizon. This Clinical Outlook discusses current and future possibilities for treating triple-negative breast cancer.

中文翻译：

---

在三阴性乳腺癌中发现阳性

三阴性乳腺癌的治疗仍以化疗为基础，缺乏靶向药物。然而，免疫治疗组合已显示出有希望的活性，通过抗体-药物偶联物的靶向化疗选择已进入临床，识别可靶向亚群的分子方法即将出现。本临床展望讨论了治疗三阴性乳腺癌的当前和未来可能性。